Annexon (ANNX) Q2 FY26 earnings call

Annexon is advancing its lead programs, tanruprubart for GBS and vonaprument for geographic atrophy, towards regulatory milestones. The GBS program is on track for a Q4 FY26 US BLA submission, supported by compelling FORWARD study data. The GA program's ARCHER II Phase III trial was strategically expanded to include a Month 24 dual primary endpoint, aiming to strengthen the long-term profile and increase overall program success, while maintaining confidence in the Q4 FY26 Month 15 readout. The company also bolstered its financial position with a new credit facility, extending its cash runway i